Deliver 24-hour access to request and review benefits investigations through our online provider portal.
This is not a complete list of all side effects that may occur.Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding.Use in Patients With Hepatic Impairment: No clinical data are available for patients with severe hepatic impairment.
Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs.Patient education: Deep vein thrombosis (DVT) (Beyond the Basics) Authors Menaka Pai, MD, FRCPC. (brand name: Xarelto) and apixaban (brand name: Eliquis).These include aspirin, P2Y 12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs).Rivaroxaban for acute deep venous thrombosis When we have a standard therapy for a disease, in this case vitamin K antagonists (VKA) for deep venous thrombosis (DVT.Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events.
Xarelto (rivaroxaban) is a Factor Xa inhibitor indicated for the prevention of deep vein thrombosis which may lead to pulmonary embolism in patients undergoing knee.
Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable.
XARELTO (rivaroxaban) tablets, for oral use Initial U.S. Approval:. 2.2 Prophylaxis of Deep Vein Thrombosis.Coadministration of enoxaparin, warfarin, aspirin, clopidogrel, and chronic NSAID use may increase the risk of bleeding.Conduct benefits investigations and provide insurance coverage information.Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants, see Drug Interactions.
Rivaroxaban (Xarelto) can be marketed for treatment of acute deep vein thrombosis and pulmonary embolism and for prevention of recurrences, the FDA announced late Friday.
Females of Reproductive Potential: Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician.